TPCA-1
Modify Date: 2024-01-02 16:25:59
TPCA-1 structure
|
Common Name | TPCA-1 | ||
|---|---|---|---|---|
| CAS Number | 507475-17-4 | Molecular Weight | 279.290 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 442.6±45.0 °C at 760 mmHg | |
| Molecular Formula | C12H10FN3O2S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 221.5±28.7 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of TPCA-1TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. |
| Name | 2-(carbamoylamino)-5-(4-fluorophenyl)thiophene-3-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. |
|---|---|
| Related Catalog | |
| Target |
IKK-2:17.9 nM (IC50) |
| In Vitro | TPCA-1 significantly represses pro-inflammatory cytokines IL-8 and GRO-α in NPECs[1]. TPCA-1 inhibit NFκB activity as well as glioma cell proliferation and IL8 expression, and at concentrations of 2.5 and 5 μM, it blocks the TNF-induced p65 translocation into the nucleus of U87 cells[2]. TPCA-1 inhibits lipopolysaccharide-induced human monocyte production of TNF-α, IL-6, and IL-8 with an IC50=170 to 320 nM[3]. |
| In Vivo | TPCA-1 (3, 10, or 20 mg/kg, i.p.) results in a dose-dependent reduction in the severity of murine collagen-induced arthritis (CIA). TPCA-1 (10 mg/kg, i.p., b.i.d.) in vivo results in significantly decreased collagen-induced T cell proliferation ex vivo[3]. |
| Kinase Assay | Recombinant human IKK-2 (residues 1-756) is expressed in baculovirus as an N-terminal GST-tagged fusion protein, and its activity is assessed using a time-resolved fluorescence resonance energy transfer assay. In brief, IKK-2 (5 nM final) diluted in assay buffer (50 mM HEPES, 10 mM MgCl2, 1 mM CHAPS, pH 7.4, with 1 mM DTT and 0.01% w/v BSA) is added to wells containing various concentrations of compound or dimethyl sulfoxide (DMSO) vehicle (3% final). The reaction is initiated by the addition of GST-IκBα substrate (25 nM final)/ATP (1 μM final), in a total volume of 30 μL. The reaction is incubated for 30 min at room temperature, then terminated by the addition of 15 μL of 50 mM EDTA. Detection reagent (15 μL) in buffer (100 mM HEPES, pH 7.4, 150 mM NaCl, and 0.1% w/v BSA) containing antiphosphoserine-IκBα-32/36 monoclonal antibody 12C2, labeled with W-1024 europium chelate, and an allophycocyanin-labeled anti-GST antibody is added, and the reaction is further incubated for 60 min at room temperature. The degree of phosphorylation of GST-IκBα is measured as a ratio of specific 665-nm energy transfer signal to reference europium 620-nm signal, using a Packard Discovery plate reader. |
| Cell Assay | Ten μLs of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from stock solution (10 mg/mL) is added to each well of 96-well plates containing glioma cells and incubated at 37°C for 2-4 h. Oxidized MTT is solubilized by adding 100 μL of 10% sodium dodecyl sulfate (SDS) in 0.01 N HCl, and plates are incubated at 37°C for 4 h in a humidified chamber. Plates are read at 570 nm on a Bio-Rad plate reader. |
| Animal Admin | Male DBA/1 OlaHsd mice are age of 6 to 8 weeks. On day 0, 10- to 12-week-old male DBA/1 mice are immunized intradermally at the base of the tail with a total of 100 μL of complete Freund's adjuvant containing 200 μg of bovine type II collagen and 250 μg of Mycobacterium tuberculosis H37Ra. On day 21, mice are boosted intradermally with 100 μL of PBS containing 200 μg of bovine type II collagen. In all studies, TPCA-1 is administered in a vehicle consisting of 0.9% DMSO, 7% dimethylacetoacetamide (DMA), and 10% Cremophor El. Etanercept (Enbrel) is administered in PBS. Where the effects of TPCA-1 and etanercept are compared, both treatment groups as well as their relevant vehicle-treated control groups are included in the same study. For prophylactic studies, TPCA-1 in vehicle or vehicle alone is administered i.p., b.i.d., beginning on day 1. Etanercept in PBS or PBS alone is administered i.p. every other day beginning on day 1. The incidence of disease exhibited by both vehicle-treated control groups (PBS- and DMSO/DMA/Cremophor-treated mice) is 100%. For therapeutic studies, administration of TPCA-1, etanercept, or their respective vehicles is initiated (day 1) once an animal exhibited a clinical score of “1” or greater for 2 consecutive days. Mice are scored daily for clinical symptoms of disease using a micrometer caliper to measure paw thickness. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 442.6±45.0 °C at 760 mmHg |
| Molecular Formula | C12H10FN3O2S |
| Molecular Weight | 279.290 |
| Flash Point | 221.5±28.7 °C |
| Exact Mass | 279.047760 |
| PSA | 126.45000 |
| LogP | 2.72 |
| Appearance of Characters | white to light brown |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.686 |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: soluble5mg/mL, clear |
|
IKK2 inhibition using TPCA-1-loaded PLGA microparticles attenuates laser-induced choroidal neovascularization and macrophage recruitment.
PLoS ONE 10 , e0121185, (2015) The inhibition of NF-κB by genetic deletion or pharmacological inhibition of IKK2 significantly reduces laser-induced choroid neovascularization (CNV). To achieve a sustained and controlled intraocula... |
|
|
Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
Virology 485 , 340-54, (2015) Vesicular stomatitis virus (VSV) is an effective oncolytic virus against most human pancreatic ductal adenocarcinoma (PDAC) cell lines. However, some PDAC cell lines are highly resistant to oncolytic ... |
|
|
Intestinal expression of Fas and Fas ligand is upregulated by bacterial signaling through TLR4 and TLR5, with activation of Fas modulating intestinal TLR-mediated inflammation.
J. Immunol. 193(12) , 6103-13, (2014) TLRs play an important role in mediating intestinal inflammation and homeostasis. Fas is best studied in terms of its function in apoptosis, but recent studies demonstrate that Fas signaling may media... |
| IKK-2 Inhibitor IV |
| 5-(4-Fluorophenyl)-2-ureidothiophene-3-carboxamide |
| TPCA-1 |
| 2-(Carbamoylamino)-5-(4-fluorophenyl)-3-thiophenecarboxamide |
| 2-(Carbamoylamino)-5-(4-fluorophenyl)thiophene-3-carboxamide |
| 3qfv |
| GW683965 GW683965A [5-(p-Fluorophenyl)-2-ureido]thiophene-3-carboxamide |
| 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- |
| 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide |